340B Action Center
The Community Access National Network (CANN) is deeply committed to the success of the 340B Drug Pricing Program, which dates back to 1992 when Congress struck a deal with pharmaceutical manufacturers to expand access to care and medication for more patients. For more information on the issues facing the 340B Program, you can access the Community Access National Network’s 340B Commission final report and reform recommendations here.
Watch our educational videos on the 340B Drug Pricing Program:
340B: A Critical Safety Net to Help Patients Access Their Medications
Legislators Must Prioritize Patients to Sustain the 340B Drug Pricing Program
The 340B Drug Pricing Program serves to improve drug accessibility and affordability for underserved patient populations, enabling them to better manage their health conditions. The program is a critical safety net to help the most vulnerable among us access their medications, including low-income individuals and under-insured or uninsured patients.
To learn more about the 340B Drug Pricing Program and the issues confronting it from the patient perspective, click on the following links:
340B By the Numbers: A Profit-Centered Reality Leaves
Patients Behind
Legislators Must Return the 340B Drug Pricing Program to its
Legislative Intent
Unfortunately, mounting evidence suggests that 340B has deviated from its intended purpose of serving patients, prompting federal and state lawmakers to propose reforms to overhaul the program.
Download our educational infographics about the 340B Drug Pricing Program:
Policy Briefs
Is there transparency in the 340B Program?
Due to a lack of transparency and oversight in the 340B program, there continues to be profiteering and abuse working against patient interests, rather than actual direct support of vulnerable patients.
Zero Savings for Vulnerable Patients Who Rely on 340B
A study concluded that 340B does not translate into savings for patients, with most patients receiving 0% in prescription medication discounts even though the medication was purchased at a 340B discount.
3X Profit Margin on 340B Medications
The average profit margin on 340B medicines dispensed through contract pharmacies is an estimated 72% compared to just 22% for non-340B medicines dispensed through independent pharmacies.
340B Hospitals Put Profits Over Charity Care
In 47 states and the District of Columbia, more than half of disproportionate share hospitals earn more in estimated 340B profit than they spend on charity care.
Is the 340B Program Serving Vulnerable Patients In Your State?
Check out our state-by-state resources on the 340B Drug Pricing Program, where legislators are pursuing dangerous program expansion that fails to address patient needs and could actually harm underserved populations.